Key Findings
Preclinical studies led by Richard J. Price, PhD, indicate that the size of a therapeutic agent significantly impacts its delivery to the brain when using focused ultrasound-mediated BBB modulation. Contrary to previous suggestions that delivery declines steadily as molecules increase in size, this research identifies an intermediate size that maximizes delivery. Specifically, 15- and 23-nanometer nanoparticles achieved higher delivery rates than both the smallest 2.3-nanometer agent and the largest 45-nanometer nanoparticles.
Technical Details
The team utilized quantitative susceptibility mapping (QSM), an MRI-based technique that detects changes in tissue magnetic properties to estimate the concentration and spatial distribution of iron oxide nanoparticles. The study tested four contrast agent sizes: a 2.3-nanometer gadolinium-based agent and iron oxide nanoparticles measuring 15, 23, and 45 nanometers. Testing was conducted on healthy mice targeting the striatum, as well as mice with gliomas. In healthy brains, delivery increased 2.6-fold between the 2.3 nm and 15 nm agents, followed by a 2.5-fold decrease between the 23 nm and 45 nm particles. No significant difference in delivery was observed between healthy mice and those with tumors for the 2.3 nm and 45 nm agents.
Background & Context
The blood-brain barrier typically restricts the passage of large or complex molecules from the bloodstream into brain tissue. To bypass this, researchers use focused ultrasound combined with intravenously administered microbubbles to temporarily and locally alter BBB permeability. This method is intended to facilitate the entry of antibodies, gene therapies, and nanoparticles that are otherwise too large to cross the BBB independently.
Significance & Outlook
The use of QSM provides a noninvasive method to quantify the amount and distribution of delivered materials. While the study measured delivery at a single time point (approximately 25 minutes post-treatment) and did not evaluate long-term safety or therapeutic effectiveness, it establishes a baseline for refining treatment plans. Future research will focus on evaluating larger agents, multiple time points, and the connection between these measurements and actual therapeutic outcomes.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
